AMPA receptor antagonists as potential anticonvulsant drugs

Current Topics in Medicinal Chemistry

Volumn 5, Issue 1, 2005, Pages 31-42

  De Sarro, Giovambattista ^a   Gitto, Rosaria ^b   Russo, Emilio ^a   Ibbadu, Guido Ferreri ^a   Barreca, Maria Letizia ^b   De Luca, Laura ^b   Chimirri, Alba ^b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

AMPA receptor antagonists; AMPAR; Anticonvulsants; Glutamate

Indexed keywords

1 (4 AMINOPHENYL) 3,4 DIHYDRO 4 METHYL 3 METHYLCARBAMOYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 4 AMINOBUTYRIC ACID; 6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; 6 (4 AMINOPHENYL) 8 CHLORO 2 METHYL 1 1H IMIDAZO[1,2 C][2,3]BENZODIAZEPINE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 6,7 DICHLORO 2 (1H) OXOQUINOLINE 3 PHOSPHONIC ACID; 6,7 DINITRO 2,3 QUINOXALINEDIONE; [1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CYTOCHROME P450 3A; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GYKI 47621; IONOTROPIC RECEPTOR; KAINIC ACID; KAINIC ACID RECEPTOR ANTAGONIST; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHTHALAZINE DERIVATIVE; PLACEBO; QUINOLINE DERIVATIVE; QUINOXALINE DERIVATIVE; S 17625; TALAMPANEL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTICONVULSANT ACTIVITY; ATAXIA; CLINICAL TRIAL; DIZZINESS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; EPILEPSY; GABAERGIC TRANSMISSION; HUMAN; KIDNEY DISEASE; MOUSE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; REVIEW; STRUCTURE ACTIVITY RELATION; X RAY DIFFRACTION;

ANIMALS; ANTICONVULSANTS; BINDING, COMPETITIVE; EPILEPSY; HUMANS; RECEPTORS, AMPA;

EID: 13444267833     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026053386999     Document Type: Review

References (118)

1. Walker, M. C.; Sander, J. W. New antiepileptic drug trials in developing countries: are they necessary? Seizure 1996, 5 165-169.
2. Bourgeois, B. F. New antiepileptic drugs. Arch. Neurol. 1998, 55, 1181-1183.
3. De Sarro, G.; Di Paola, E. D.; Gareri, P.; Gallelli, L.; Scotto, G.; De Sarro, A. Effects of some AMPA receptor antagonists on the development of tolerance in epilepsy-prone rats and in pentylenetetrazole kindled rats. Eur. J. Pharmacol. 1999, 368, 149-159.
4. Meldrum, B. Do preclinical seizure models preselect certain adverse effects of antiepileptic drugs. Epilepsy Res. 2002, 50, 33-40.
5. Chapman, A. G.; Hart, G. P. Anticonvulsant drug action and regional neurotransmitter amino acid changes. J. Neural. Transm. 1988, 72, 201-212.
6. Meldrum, B. S.; Chapman, A. G. Excitatory amino acid receptors and antiepileptic drug development. Adv. Neurol. 1999 79, 965-978.
7. Dingledine, R.; Borges, K.; Bowie, D.; Traynelis, S. F. The glutamate receptor ion channels. Pharmacol. Rev. 1999, 51 7-61.
8. Sugiyama, H.; Ito, I.; Hirono, C. A new type of glutamate receptor linked to inositol phospholipid metabolism. Nature 1987 325, 531-533.
9. Sladeczek, F.; Pin, J. P.; Recasens, M.; Bockaert, J.; Weiss, S. Glutamate stimulates inositol phosphate formation in striatal neurones. Nature 1985, 317, 717-719.
10. Tanabe, Y.; Masu, M.; Ishii, T.; Shigemoto, R.; Nakanishi, S. A family of metabotropic glutamate receptors. Neuron 1992, 8, 169-179.
11. Houamed, K. M.; Kuijper, J. L.; Gilbert, T. L.; Haldeman, B. A.; O'Hara, P. J.; Mulvihill, E. R.; Almers, W.; Hagen, F. S. Cloning, expression, and gene structure of a G protein-coupled glutamate receptor from rat brain. Science 1991, 252, 1318-1321.
12. Jingami, H.; Nakanishi, S.; Morikawa, K. Structure of the metabotropic glutamate receptor. Curr. Opin. Neurobiol. 2003, 13, 271-278.
13. Stensbol, T. B.; Madsen, U.; Krogsgaard-Larsen, P. The AMPA receptor binding site: focus on agonists and competitive antagonists. Curr. Pharm. Des. 2002, 8, 857-872.
14. Rosenmund, C.; Stern-Bach, Y.; Stevens, C. F. The tetrameric structure of a glutamate receptor channel. Science 1998, 280, 1596-1599.
15. Sutcliffe, M. J.; Wo, Z. G.; Oswald, R. E. Three-dimensional models of non-NMDA glutamate receptors. Biophys. J. 1996, 70, 1575-1589.
16. Sutcliffe, M. J.; Smeeton, A. H.; Wo, Z. G.; Oswald, R. E. Three-dimensional models of glutamate receptors. Biochem. Soc. Trans 1998, 26, 450-458.
17. Armstrong, N.; Gouaux, E. Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core. Neuron 2000, 28 165-181.
18. De Luca, L.; Macchiarulo, A.; Costantino, G.; Barreca, M. L.; Gitto, R.; Chimirri, A.; Pellicciari, R. Binding modes of noncompetitive AMPA antagonists: a computational approach. Farmaco 2003, 58, 107-113.
19. Chenard, B. L.; Menniti, F. S. Antagonists selective for NMDA receptors containing the NR2B subunit. Curr. Pharm. Des. 1999 5, 381-404.
20. Chimirri, A.; Gitto, R.; Zappala, M. AMPA receptor antagonists. Exp. Opin. Ther. Patents 1999, 9, 557-570.
21. Nikam, S. S.; Kornberg, B. E. AMPA receptor antagonists. Curr. Med. Chem. 2001, 8, 155-170.
22. Hogner, A.; Greenwood, J. R.; Liljefors, T.; Lunn, M. L.; Egebjerg, J.; Larsen, I. K.; Gouaux, E.; Kastrup, J. S. Competitive antagonism of AMPA receptors by ligands of different classes: crystal structure of ATPO bound to the GluR2 ligand-binding core, in comparison with DNQX. J. Med. Chem. 2003, 46, 214-221.
23. Kornberg, B. E.; Nikam, S. S. Sulfonamide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists. United States Patent 6,096,744 2000.
24. Auberson, Y. P. Competitive AMPA antagonism: a novel mechanism for antiepileptic drugs? Drugs of the Future 2001, 26, 463-471.
25. Bigge, C. F.; Malone, T. C.; Schelkun, R. M.; Yi, C. S. Glutamate (ampa/kainate) receptor antagonists: N-substituted fused azacycloalkylquinoxalinediones. Pfizer Inc. US 6057313 2000.
26. Cordi, A. A.; Desos, P.; Randle, J. C.; Lepagnol, J. Structure-activity relationships in a series of 3-sulfonylamino-2-(1H)-quinolones, as new AMPA/kainate and glycine antagonists, Bioorg. Med. Chem. 1995, 3, 129-141.
27. Cordi, A. A.; Desos, P.; Ruano, E.; Al-Badri, H.; Fugier, C.; Chapman, A. G.; Meldrum, B. S.; Thomas, J. Y.; Roger, A.; Lestage, P. Novel quinolinone-phosphonic acid AMPA antagonists devoid of nephrotoxicity. Farmaco 2002, 57, 787-802.
28. Mignani, S.; Bohme, G. A.; Boireau, A.; Cheve, M.; Damour, D.; Debono, M. W.; Genevois-Borella, A.; Imperato, A.; Jimonet, P.; Pratt, J.; Randle, J. C.; Ribeill, Y.; Vuilhorgne, M.; Stutzmann, J. M. 8-Methylureido-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno [1,2-e]pyrazines: highly potent in vivo AMPA antagonists. Bioorg. Med. Chem. Lett. 2000, 10, 591-596.
29. Stutzmann, J. M.; Bohme, G. A.; Boireau, A.; Damour, D.; Debono, M. W.; Genevois-Borella, A.; Imperato, A.; Jimonet, P.; Pratt, J.; Randle, J. C.; Ribeill, Y.; Vuilhorgne, M.; Mignani, S. 4,10-Dihydro-4-oxo-4H-imidazo[1, 2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity. Bioorg. Med. Chem. Lett. 2000, 10, 1133-1137.
30. Jimonet, P.; Cheve, M.; Bohme, G. A.; Boireau, A.; Damour, D.; Debono, M. W.; Genevois-Borella, A.; Imperato, A.; Pratt, J.; Randle, J. C.; Ribeill, Y.; Stutzmann, J. M.; Vuilhorgne, M.; Mignani, S. 8-Methylureido-10-amino-10-methyl-imidazo[1,2-a]indeno[1,2-e] pyrazine-4-ones: highly in vivo potent and selective AMPA receptor antagonists. Bioorg. Med. Chem. 2000, 8, 2211-2217.
31. Pratt, J.; Jimonet, P.; Bohme, G. A.; Boireau, A.; Damour, D.; Debono, M. W.; Genevois-Borella, A.; Randle, J. C.; Ribeill, Y.; Stutzmann, J. M.; Vuilhorgne, M.; Mignani, S. Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]indeno[1,2-e]pyrazin-8- and -9-carboxylic (acetic) acid AMPA antagonists. Bioorg. Med. Chem. Lett. 2000, 10, 2749-2754.
32. Jimonet, P.; Bohme, G. A.; Bouquerel, J.; Boireau, A.; Damour, D.; Debono, M. W.; Genevois-Borella, A.; Hardy, J. C.; Hubert, P.; Manfre, F.; Nemecek, P.; Pratt, J.; Randle, J. C.; Ribeill, Y.; Stutzmann, J. M.; Vuilhorgne, M.; Mignani, S. Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin- 2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action. Bioorg. Med. Chem. Lett. 2001, 11, 127-132.
33. Stutzmann, J. M.; Bohme, G. A.; Boireau, A.; Damour, D.; Debono, M. W., Genevois-Borella, A.; Jimonet, P.; Pratt, J.; Randle, J. C.; Ribeill, Y.; Vuilhorgne, M.; Mignani, S. Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidazo[1,2-a]indeno[1, 2-e]pyrazin-2-carboxylic acid derivatives. Bioorg. Med. Chem. Lett. 2001, 11, 1205-1210.
34. Mignani, S.; Bohme, G. A.; Birraux, G.; Boireau, A.; Jimonet, P.; Damour, D.; Genevois-Borella, A.; Debono, M. W.; Pratt, J.; Vuilhorgne, M.; Wahl, F.; Stutzmann, J. M. 9-Carboxymethyl-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one- 2-carbocyl ic acid (RPR117824): selective anticonvulsive and neuroprotective AMPA antagonist. Bioorg. Med. Chem. 2002, 10, 1627-1637.
35. Solyom, S. Research on new AMPA antagonists of 2,3-benzodiazepine type. Pharmazie 2001, 56 Suppl. 1, S62-66.
36. Donevan, S. D.; Rogawski, M. A. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 1993, 10, 51-59.
37. Szabados, T.; Gigler, G.; Gacsalyi, I.; Gyertyan, I.; Levay, G. Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655. Brain Res. Bull. 2001, 55, 387-391.
38. Donevan, S. D.; Yamaguchi, S.; Rogawski, M. A. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity. J Pharmacol. Exp. Ther. 1994, 271, 25-29.
39. Ruel, J.; Guitton, M. J.; Puell, J. L. Negative allosteric modulation of AMPA-preferring receptors by the selective isomer GYKI 53784 (LY303070), a specific non-competitive AMPA antagonist. CNS Drug Rev. 2002, 8, 235-254.
40. Vilagi, I.; Takacs, J.; Gulyas-Kovacs, A.; Banczerowski-Pelyhe, I.; Tarnawa, I. Protective effect of the antiepileptic drug candidate talampanel against AMPA-induced striatal neurotoxicity in neonatal rats. Brain Res. Bull. 2002, 59 35-40.
41. Andrási, F. Talampanel. Antiepileptic, Neuroprotectant, Skeletal muscle relaxant. Drugs of the Future 2001, 26, 754-756.
42. Bialer, M.; Johannessen, S. I.; Kupferberg, H. J.; Levy, R. H.; Loiseau, P.; Perucca, E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 2001, 43, 11-58.
43. Hamori, T.; Solyom, S.; Berzsenyi, P.; Andrasi, F.; Tarnawa, I. Structural analogues of some highly active non-competitive AMPA antagonists. Bioorg. Med. Chem. Lett. 2000, 10, 899-902.
44. Gitto, R.; Zappalá, M.; De Sarro, G.; Chimirri, A. Design and development of 2,3-benzodiazepine (CFM) noncompetitive AMPA receptor antagonists. Farmaco 2002, 57, 129-134.
45. Abraham, G.; Solyom, S.; Csuzdi, E.; Berzsenyi, P.; Ling, I.; Tarnawa, I.; Hamori, T.; Pallagi, I.; Horvath, K.; Andrasi, F.; Kapus, G.; Harsing, L. G., Jr.; Kiraly, I.; Patthy, M.; Horvath, G. New non competitive AMPA antagonists. Bioorg. Med. Chem. 2000, 8 2127-2143.
46. Chimirri, A.; De Sarro, G.; De Sarro, A.; Gitto, R.; Grasso, S.; Quartarone, S.; Zappala, M.; Giusti, P.; Libri, V.; Constanti, A.; Chapman, A. G. 1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: novel AMPA receptor antagonists. J. Med. Chem. 1997, 40, 1258-1269.
47. Chimirri, A.; De Sarro, G.; De Sarro, A.; Gitto, R.; Quartarone, S.; Zappala, M.; Constanti, A.; Libri, V. 3,5-Dihydro-4H-2,3-benzodiazepine-4-thiones: a new class of AMPA receptor antagonists. J. Med. Chem. 1998, 41, 3409-3416.
48. De Sarro, G.; Ferreri, G.; Gareri, P.; Russo, E.; De Sarro, A.; Gitto, R.; Chimirri, A. Comparative anticonvulsant activity of some 2,3-benzodiazepine derivatives in rodents. Pharmacol. Biochem. Behav. 2003, 74, 595-602.
49. De Sarro, G.; Rizzo, M.; Sinopoli, V. A.; Gitto, R.; De Sarro, A.; Zappala, M.; Chimirri, A. Relationship between anticonvulsant activity and plasma level of some 2,3-benzodiazepines in genetically epilepsy-prone rats. Pharmacol .Biochem. Behav. 1998, 61 215-220.
50. De Sarro, G.; Rizzo, M.; Spagnolo, C.; Gitto, R.; De Sarro, A.; Scotto, G.; Zappala, M.; Chimirri, A. Anticonvulsant activity and plasma level of 2,3-benzodiazepin-4-ones (CFMs) in genetically epilepsy-prone rats. Pharmacol. Biochem. Behav. 1999, 63 621-627.
51. Grasso, S.; De Sarro, G.; De Sarro, A.; Micale, N.; Zappala, M.; Puia, G.; Baraldi, M.; De Micheli, C. Synthesis and anticonvulsant activity of novel and potent 2,3- benzodiazepine AMPA/kainate receptor antagonists. J. Med. Chem. 1999, 42, 4414-4421.
52. De Sarro, A.; De Sarro, G.; Gitto, R.; Grasso, S.; Micale, N.; Quartarone, S.; Zappala, M. 7,8-Methylenedioxy-4H-2,3-benzodiazepin-4-ones as novel AMPA receptor antagonists. Bioorg. Med. Chem. Lett. 1998, 8, 971-976.
53. De Sarro, G.; Chimirri, A.; De Sarro, A.; Gitto, R.; Grasso, S.; Giusti, P.; Chapman, A. G. GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice. Eur J. Pharmacol. 1995 294, 411-422.
54. Bevacqua, F.; Basso, A.; Gitto, R.; Bradley, M.; Chimirri, A. Solid-phase Friedel-Crafts acylation on polystyrene resins-synthesis of antiepiletic 1-aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones. Tetrahedron Letters 2001, 42, 7683-7685.
55. Zappala, M.; Gitto, R.; Bevacqua, F.; Quartarone, S.; Chimirri, A.; Rizzo, M.; De Sarro, G.; De Sarro, A. Synthesis and evaluation of pharmacological and pharmacokinetic properties of 11H-[1,2,4]triazolo[4,5-c][2,3]benzodiazepin-3(2H)-ones. J. Med. Chem. 2000, 43, 4834-4839.
56. Chimirri, A.; Gitto, R.; Quartarone, S.; Orlando, V.; De Sarro, A.; De Sarro, G. B. Synthesis and pharmacological properties of new 3-ethoxycarbonyl-11H-[1,2,4]triazolo[4,5-c][2,3]benzodiazepines. Farmaco 2002, 57, 759-763.
57. Gitto, R.; Orlando, V.; Quartarone, S.; De Sarre, G.; De Sarro, A.; Russo, E.; Ferreri, G.; Chimirri, A. Synthesis and evaluation of pharmacological properties of novel annelated 2,3-benzodiazepine derivatives. J. Med. Chem. 2003, 46, 3758-3761.
58. Pelletier, J. C.; Hesson, D. P.; Jones, K. A.; Costa, A. M. Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J. Med. Chem. 1996, 39, 343-346.
59. Pei, X. F.; Sturgess, M. A.; Valenzuela, C. F.; Maccecchini, M. L. Allosteric modulators of the AMPA receptor: novel 6-substituted dihydrophthalazines. Bioorg. Med. Chem. Lett. 1999, 9, 539-542.
60. Grasso, S.; De Sarro, G.; De Sarro, A.; Micale, N.; Zappala, M.; Puja, G.; Baraldi, M.; De Micheli, C. Synthesis and anticonvulsant activity of novel and potent 6,7- methylenedioxyphthalazin-1(2H)-ones. J. Med. Chem. 2000, 43, 2851-2859.
61. Gitto, R.; Chimirri, A.; Zappala, M.; De Sarro, G.; De Sarro, A. Synthesis and pharmacological evaluation of 4-aryl-6,7-dimethoxyphthalazines as anticonvulsant agents. Medicinal Chemistry Research 2000, 10, 1-10.
62. Li, B. Q.; Pei, X. F.; Maccecchini, M. Novel sulfur containing dihydrophthalazine antagonists of AMPA receptors. Washington DC, USA. 220th ACS Meeting 2000, MEDI 212.
63. Chenard, B. L.; Welch, W. M., Blake, J. F.; Butler, T. W.; Reinhold, A.; Ewing, F. E.; Menniti, F. S.; Pagnozzi, M. J. Quinazolin-4-one alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists: structure-activity relationship of the C-2 side chain tether. J. Med. Chem. 2001, 44, 1710-1717.
64. Chenard, B. L.; Menniti, F. S.; Pagnozzi, M. J.; Shenk, K. D.; Ewing, F. E.; Welch, W. M. Methaqualone derivatives are potent noncompetitive AMPA receptor antagonists. Bioorg. Med. Chem. Lett. 2000, 10, 1203-1205.
65. Menniti, F. S.; Buchan, A. M.; Chenard, B. L.; Critchett, D. J.; Ganong, A. H.; Guanowsky, V.; Seymour, P. A.; Welch, W. M. CP-465,022, a selective noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo. Stroke 2003 34, 171-176.
66. Lazzaro, J. T.; Paternain, A. V.; Lerma, J.; Chenard, B. L.; Ewing, F. E.; Huang, J.; Welch, W. M.; Ganong, A. H.; Menniti, F. S. Functional characterization of CP-465,022, a selective, noncompetitive AMPA receptor antagonist. Neuropharmacology 2002, 42, 143-153.
67. Welch, W. M.; Ewing, F. E.; Huang, J.; Menniti, F. S.; Pagnozzi, M. J.; Kelly, K.; Seymour, P. A.; Guanowsky, V.; Guhan, S.; Guinn, M. R.; Critchett, D.; Lazzaro, J.; Ganong, A. H.; DeVries, K. M.; Staigers, T. L.; Chenard, B. L. Atropisomeric quinazolin-4-one derivatives are potent noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists. Bioorg. Med. Chem. Lett. 2001, 11, 177-181.
68. Menniti, F. S.; Chenard, B. L.; Collins, M. B.; Ducat, M. F.; Elliott, M. L.; Ewing, F. E.; Huang, J. I.; Kelly, K. A.; Lazzaro, J. T.; Pagnozzi, M. J.; Weeks, J. L.; Welch, W. M.; White, W. F. Characterization of the binding site for a novel class of noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonists. Mol. Pharmacol. 2000, 58, 1310-1317.
69. Yamashita, H.; Ohno, K.; Amada, Y.; Hattori, H.; Ozawa-Funatsu, Y.; Toya, T.; Inami, H.; Shishikura, J.; Sakamoto, S.; Okada, M.; Yamaguchi, T. Effects of 2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido[3.2-e]-1, 3-thiazin-4-one (YM928), an orally active alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, in models of generalized epileptic seizure in mice and rats. J. Pharmacol. Exp. Ther. 2004, 308, 127-133.
70. Yamashita, H.; Ohno, K.; Inami, H.; Shishikura, J.; Sakamoto, S.; Okada, M.; Yamaguchi, T. Suppression of fully kindled seizure and retardation of kindling acquisition by YM928 in the rat kindling model of epilepsy. Eur. J. Pharmacol. 2004, 494, 147-154.
71. Weiser, T.; Brenner, M.; Palluk, R.; Bechtel, W. D.; Ceci, A.; Brambilla, A.; Ensinger, H. A.; Sagrada, A.; Wienrich, M. BIIR 561 CL: a novel combined antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors and voltage-dependent sodium channels with anticonvulsive and neuroprotective properties. J. Pharmacol. Exp. Ther. 1999, 289, 1343-1349.
72. Feigin, V. Irampanel Boehringer Ingelheim. Curr. Opin. Investig. Drugs 2002, 3, 908-910.
73. Weiser, T.; Wienrich, M.; Brenner, M.; Kubiak, R.; Weckesser, G.; Palluk, R. The AMPA receptor/Na(+) channel blocker BIIR 561 CL is protective in a model of global cerebral ischaemia. Eur. J. Pharmacol. 2001, 421, 165-170.
74. Gitto, R.; Barreca, M. L.; De Luca, L.; De Sarro, G.; Ferreri, G.; Quartarone, S.; Russo, E.; Constanti, A.; Chimirri, A. Discovery of a novel and highly potent noncompetitive AMPA receptor antagonist. J. Med. Chem. 2003, 46, 197-200.
75. Gitto, R.; Caruso, R.; Orlando, V.; Quartarone, S.; Barreca, M. L.; Ferreri, G.; Russo, E.; De Sarro, G.; Chimirri, A. Synthesis and anticonvulsant properties of tetrahydroisoquinoline derivatives. Farmaco 2004, 59, 7-12.
76. Ferreri, G.; Chimirri, A.; Russo, E.; Gitto, R.; Gareri, P.; De Sarro, A.; De Sarro, G. Comparative anticonvulsant activity of N-acetyl-1-aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives in rodents. Pharmacol. Biochem. Behav. 2004, 77, 85-94.
77. Barreca, M. L.; Gitto, R.; Quartarone, S.; De Luca, L.; De Sarro, G.; Chimirri, A. Pharmacophore modeling as an efficient tool in the discovery of novel noncompetitive AMPA receptor antagonists. J. Chem. Inf. Comput. Sci. 2003, 43, 651-655.
78. Macchiarulo, A.; De Luca, L.; Costantino, G.; Barreca, M. L.; Gitto, R.; Pellicciari, R.; Chimirri, A. QSAR study of anticonvulsant negative allosteric modulators of the AMPA receptor. J. Med. Chem. 2004, 47, 1860-1863.
79. Bisaga, A.; Krzascik, P.; Jankowska, E.; Palejko, W.; Kostowski, W.; Danysz, W. Effect of glutamate receptor antagonists on N-methyl-D-aspartate- and (S)-alpha-amino-3-hydroxy-5-methyl- 4-isoxazolepropionic acid-induced convulsant effects in mice and rats. Eur. J. Pharmacol. 1993, 242, 213-220.
80. Chapman, A. G.; Smith, S. E.; Meldrum, B. S. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy Res. 1991, 9, 92-96.
81. Durmuller, N.; Craggs, M.; Meldrum, B. S. The effect of the non-NMDA receptor antagonist GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res. 1994, 17, 167-174.
82. Lallement, G.; Pernot-Marino, I.; Foquin-Tarricone, A.; Baubichon, D.; Piras, A.; Blanchet, G.; Carpentier, P. Antiepileptic effects of NBQX against soman-induced seizures. Neuroreport 1994 5, 425-428.
83. Loscher, W.; Honack, D. Over-additive anticonvulsant effect of memantine and NBQX in kindled rats. Eur. J. Pharmacol. 1994 259, R3-5.
84. Loscher, W.; Wahnschaffe, U.; Mevissen, M.; Lerchl, A.; Stamm, A. Effects of weak alternating magnetic fields on nocturnal melatonin production and mammary carcinogenesis in rats. Oncology 1994, 51, 288-295.
85. Meldrum, B. S.; Craggs, M. D.; Durmuller, N.; Smith, S. E.; Chapman, A. G. The effects of AMPA receptor antagonists on kindled seizures and on reflex epilepsy in rodents and primates. Epilepsy Res. Suppl. 1992, 9, 307-311.
86. Namba, T.; Morimoto, K.; Sato, K.; Yamada, N.; Kuroda, S. Antiepileptogenic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy. Brain Res. 1994, 638, 36-44.
87. Ohmori, J.; Sakamoto, S.; Kubota, H.; Shimizu-Sasamata, M.; Okada, M.; Kawasaki, S.; Hidaka, K.; Togami, J.; Furuya, T.; Murase, K. 6-(1H-imidazol-1-yl)-7-nitro-2,3 (1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor. J. Med. Chem. 1994, 37, 467-475.
88. Ohmori, J.; Shimizu-Sasamata, M.; Okada, M.; Sakamoto, S. Novel AMPA receptor antagonists: synthesis and structure-activity relationships of 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)- quinoxalinedione and related compounds. J. Med. Chem. 1996, 39, 3971-3979.
89. Ohmori, J.; Kubota, H.; Shimizu-Sasamata, M.; Okada, M.; Sakamoto, S. Novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonists: synthesis and structure-activity relationships of 6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-pyrido [2,3-b]pyrazinedione and related compounds. J. Med. Chem. 1996, 39, 1331-1338.
90. Ohmori, J.; Shimizu-Sasamata, M.; Okada, M.; Sakamoto, S. 8-(1H-imidazol-1-yl)-7-nitro-4(5H)-imidazo[1,2-alpha]quinoxalinone and related compounds: synthesis and structure-activity relationships for the AMPA-type non-NMDA receptor. J. Med. Chem. 1997, 40, 2053-2063.
91. Steppuhn, K. G.; Turski, L. Modulation of the seizure threshold for excitatory amino acids in mice by antiepileptic drugs and chemoconvulsants. J. Pharmacol. Exp. Ther. 1993, 265, 1063-1070.
92. Turski, L.; Jacobsen, P.; Honore, T.; Stephens, D. N. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline. J. Pharmacol. Exp. Ther. 1992, 260, 742-747.
93. Yamaguchi, S.; Donevan, S. D.; Rogawski, M. A. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. 1993, 15, 179-184.
94. Young, D.; Dragunow, M. Non-NMDA glutamate receptors are involved in the maintenance of status epilepticus. Neuroreport 1993, 5, 81-83.
95. Young, D.; Dragunow, M. MK-801 and NBQX prevent electrically induced status epilepticus. Neuroreport 1994, 5, 1481-1484.
96. Zarnowski, T.; Kleinrok, Z.; Turski, W. A.; Czuczwar, S. J. 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline enhances the protective activity of common antiepileptic drugs against maximal electroshock-induced seizures in mice. Neuropharmacology 1993 32, 895-900.
97. Takano, Y.; Shiga, F.; Asano, J.; Ando, N.; Uchiki, H.; Anraku, T. Synthesis and AMPA receptor antagonistic activity of a novel class of quinoxalinecarboxylic acid with a substituted phenyl group at the C-7 position. Bioorg. Med. Chem. Lett. 2003, 13, 3521-3525.
98. Loscher, W.; Rundfeldt, C.; Honack, D. Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy. Eur. J. Neurosci. 1993, 5, 1545-1550.
99. Zappala, M.; Gitto, R.; Bevacqua, F.; Quartarone, S.; Chimirri, A.; Rizzo, M.; De Sarro, G.; De Sarro, A. Synthesis and evaluation of pharmacological and pharmacokinetic properties of 11H-[1,2,4]triazolo[4,5-c][2,3]benzodiazepin-3(2H)-ones. J. Med. Chem. 2000, 43, 4834-4839.
100. Grasso, S.; De Sarro, G.; De Sarro, A.; Micale, N.; Polimeni, S.; Zappala, M.; Puia, G.; Baraldi, M.; De Micheli, C. Synthesis and anticonvulsant activity of novel and potent 1-aryl-7,8-methylenedioxy-1,2,3,5-tetrahydro-4H-2, 3-benzodiazepin-4-ones. Bioorg. Med. Chem. Lett. 2001, 11, 463-466.
101. Ramakers, G. M.; Peeters, B. W.; Vossen, J. M.; Coenen, A. M. CNQX, a new non-NMDA receptor antagonist, reduces spike wave discharges in the WAG/Rij rat model of absence epilepsy. Epilepsy Res. 1991 9, 127-131.
102. Kaminski, R. M.; Van Rijn, C. M.; Turski, W, A.; Czuczwar, S. J.; Van Luijtelaar, G. AMPA and GABA(B) receptor antagonists and their interaction in rats with a genetic form of absence epilepsy. Eur. J. Pharmacol. 2001, 430, 251-259.
103. Jakus, R.; Graf, M.; Ando, R. D.; Balogh, B.; Gacsalyi, I.; Levay, G.; Kantor, S.; Bagdy, G. Effect of two noncompetitive AMPA receptor antagonists GYKI 52466 and GYKI 53405 on vigilance, behavior and spike-wave discharges in a genetic rat model of absence epilepsy. Brain Res 2004, 1008, 236-244.
104. Armstrong, D. D. The neuropathology of temporal lobe epilepsy. J. Neuropathol. Exp. Neurol. 1993, 52, 433-443.
105. Ben-Ari, Y. Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 1985, 14, 375-403.
106. Du, F.; Whetsell, W. O., Jr.; Abou-Khalil, B.; Blumenkopf B.; Lothman, E. W.; Schwarcz, R. Preferential neuronal loss in layer III of the entorhinal cortex in patients with temporal lobe epilepsy. Epilepsy Res. 1993, 16, 223-233.
107. Hudson, L. P.; Munoz, D. G.; Miller, L.; McLachlan, R. S.; Girvin, J. P.; Blume, W. T. Amygdaloid sclerosis in temporal lobe epilepsy. Ann. Neurol. 1993, 33, 622-631.
108. Wasterlain, C. G.; Fujikawa, D. G.; Penix, L.; Sankar, R. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia 1993, 34 Suppl. 1, S37-53.
109. Saukkonen, A.; Kalviainen, R.; Partanen, K.; Vainio, P.; Riekkinen, P.; Pitkanen, A. Do seizures cause neuronal damage? A MRI study in newly diagnosed and chronic epilepsy. Neuroreport 1994 6, 219-223.
110. Lees, G. J.; Leong, W. The non-NMDA glutamate antagonist NBQX blocks the local hippocampal toxicity of kainic acid, but not the diffuse extrahippocampal damage. Neurosci. Lett. 1992, 143, 39-42.
111. Lees, G. J.; Leong, W. Differential effects of NBQX on the distal and local toxicity of glutamate agonists administered intrahippocampally. Brain Res. 1993, 628, 1-7.
112. Lees, G. J.; Leong, W. Synergy between diazepam and NBQX in preventing neuronal death caused by non-NMDA agonists. Neuroreport 1994, 5, 2149-2152.
113. Virgili, M.; Contestabile, A.; Barnabei, O. Simultaneous blockade of non-NMDA ionotropic receptors and NMDA receptor-associated ionophore partially protects hippocampal slices from protein synthesis impairment due to simulated ischemia. Hippocampus 1995, 5 91-97.
114. Penix, L. P.; Wasterlain, C. G. Selective protection of neuropeptide containing dentate hilar interneurons by non-NMDA receptor blockade in an animal model of status epilepticus. Brain Res. 1994, 644, 19-24.
115. Chapman, A. G.; Elwes, R. D.; Millan, M. H.; Polkey, C. E.; Meldrum, B. S. Role of glutamate and aspartate in epileptogenesis; contribution of microdialysis studies in animal and man. Epilepsy Res. Suppl. 1996, 12, 239-246.
116. Chapman, A. G. Glutamate receptors in epilepsy. Prog. Brain Res. 1998, 116, 371-383.
117. de Lanerolle, N. C.; Eid, T.; von Campe, G.; Kovacs, L; Spencer, D. D.; Brines, M. Glutamate receptor subunits GluR1 and GluR2/3 distribution shows reorganization in the human epileptogenic hippocampus. Eur. J. Neurosci. 1998, 10, 1687-1703.
118. De Sarro, G.; Chimirri, A.; Meldrum, B. S. Group III mGlu receptor agonists potentiate the anticonvulsant effect of AMPA and NMDA receptor block. Eur. J. Pharmacol. 2002, 451, 55-61.